Prevention and Adjuvant Therapy in Breast Cancer

Faithlore P. Gardner; Edith A. Perez

doi:10.1002/9781118589199.ch81

Prevention and Adjuvant Therapy in Breast Cancer

Faithlore P. Gardner, Edith A. Perez

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter presents a series of questions and answers on prevention and adjuvant therapy in breast cancer. It commences with a discourse on best strategies for breast cancer prevention in postmenopausal women, and ends with the optimal adjuvant approach for patients with resected HER2-positive invasive breast cancer. The chapter also discusses on the role of CYP2D6 in the efficacy and tolerability of tamoxifen in the chemoprevention setting, best adjuvant endocrine therapy for patients with hormone-positive invasive breast cancer, and real cardiovascular risk of anthracyclines used for the treatment of breast cancer.

Original language	English (US)
Title of host publication	Cancer Consult
Subtitle of host publication	Expertise for Clinical Practice
Publisher	Wiley-Blackwell
Pages	523-531
Number of pages	9
ISBN (Electronic)	9781118589199
ISBN (Print)	9781118589212
DOIs	https://doi.org/10.1002/9781118589199.ch81
State	Published - Jun 20 2014

Keywords

Adjuvant endocrine therapy
Anthracyclines
Breast cancer
CYP2D6

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781118589199.ch81

Cite this

@inbook{a51ef76c8c544e8ba0dc72886504fe96,

title = "Prevention and Adjuvant Therapy in Breast Cancer",

abstract = "This chapter presents a series of questions and answers on prevention and adjuvant therapy in breast cancer. It commences with a discourse on best strategies for breast cancer prevention in postmenopausal women, and ends with the optimal adjuvant approach for patients with resected HER2-positive invasive breast cancer. The chapter also discusses on the role of CYP2D6 in the efficacy and tolerability of tamoxifen in the chemoprevention setting, best adjuvant endocrine therapy for patients with hormone-positive invasive breast cancer, and real cardiovascular risk of anthracyclines used for the treatment of breast cancer.",

keywords = "Adjuvant endocrine therapy, Anthracyclines, Breast cancer, CYP2D6",

author = "Gardner, {Faithlore P.} and Perez, {Edith A.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley and Sons, Inc.",

year = "2014",

month = jun,

day = "20",

doi = "10.1002/9781118589199.ch81",

language = "English (US)",

isbn = "9781118589212",

pages = "523--531",

booktitle = "Cancer Consult",

publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Prevention and Adjuvant Therapy in Breast Cancer

AU - Gardner, Faithlore P.

AU - Perez, Edith A.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - This chapter presents a series of questions and answers on prevention and adjuvant therapy in breast cancer. It commences with a discourse on best strategies for breast cancer prevention in postmenopausal women, and ends with the optimal adjuvant approach for patients with resected HER2-positive invasive breast cancer. The chapter also discusses on the role of CYP2D6 in the efficacy and tolerability of tamoxifen in the chemoprevention setting, best adjuvant endocrine therapy for patients with hormone-positive invasive breast cancer, and real cardiovascular risk of anthracyclines used for the treatment of breast cancer.

AB - This chapter presents a series of questions and answers on prevention and adjuvant therapy in breast cancer. It commences with a discourse on best strategies for breast cancer prevention in postmenopausal women, and ends with the optimal adjuvant approach for patients with resected HER2-positive invasive breast cancer. The chapter also discusses on the role of CYP2D6 in the efficacy and tolerability of tamoxifen in the chemoprevention setting, best adjuvant endocrine therapy for patients with hormone-positive invasive breast cancer, and real cardiovascular risk of anthracyclines used for the treatment of breast cancer.

KW - Adjuvant endocrine therapy

KW - Anthracyclines

KW - Breast cancer

KW - CYP2D6

UR - http://www.scopus.com/inward/record.url?scp=84946402582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946402582&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch81

DO - 10.1002/9781118589199.ch81

M3 - Chapter

AN - SCOPUS:84946402582

SN - 9781118589212

SP - 523

EP - 531

BT - Cancer Consult

PB - Wiley-Blackwell

ER -

Prevention and Adjuvant Therapy in Breast Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this